SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #DDW2021–Freenome, the privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood draw, today announced results from two different studies using “CRC – Microsimulation of Adenoma Progression and Screening”, or CRC-MAPS(TM), a novel semi-Markov microsimulation model of the adenoma-carcinoma pathway. The first study revealed that changes in adenoma sensitivity have a greater impact